CSL Ltd CSL
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CSL is a good fit for your portfolio.
News
-
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
-
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
-
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
-
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
-
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
-
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
-
CSL Says 1st Half Profit Rises, Boosts Dividend — Update
-
CSL Says 1st Half Profit Rises, Boosts Dividend
Trading Information
- Previous Close Price
- A$278.97
- Day Range
- A$278.27–282.98
- 52-Week Range
- A$228.65–312.99
- Bid/Ask
- A$278.35 / A$278.50
- Market Cap
- A$134.56 Bil
- Volume/Avg
- 776,115 / 725,422
Key Statistics
- Price/Earnings (Normalized)
- 28.43
- Price/Sales
- 6.32
- Dividend Yield (Trailing)
- 1.37%
- Dividend Yield (Forward)
- 1.37%
- Total Yield
- 1.37%
Company Profile
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 30,000
- Website
- https://www.csl.com
Competitors
Valuation
|
Metric
|
CSL
|
SNY
|
GRF.P
|
|---|---|---|---|
Price/Earnings (Normalized) | 28.43 | 10.04 | 24.77 |
Price/Book Value | 5.28 | 1.56 | 0.69 |
Price/Sales | 6.32 | 2.38 | 0.61 |
Price/Cash Flow | 32.99 | 11.66 | 6.92 |
Price/Earnings
CSL
SNY
GRF.P
Financial Strength
|
Metric
|
CSL
|
SNY
|
GRF.P
|
|---|---|---|---|
Quick Ratio | 0.95 | 0.83 | 0.72 |
Current Ratio | 2.15 | 1.27 | 2.48 |
Interest Coverage | 7.21 | 11.03 | 1.28 |
Quick Ratio
CSL
SNY
GRF.P
Profitability
|
Metric
|
CSL
|
SNY
|
GRF.P
|
|---|---|---|---|
Return on Assets (Normalized) | 8.11% | 8.05% | 1.30% |
Return on Equity (Normalized) | 18.17% | 14.38% | 4.69% |
Return on Invested Capital (Normalized) | 10.94% | 10.85% | 3.45% |
Return on Assets
CSL
SNY
GRF.P
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bknsygkblb | Dgrj | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qytsykcy | Tnlvwx | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rbxxyff | Rsjqz | $99.6 Bil | |
MRNA
| Moderna Inc | Dxbqskqk | Xbh | $38.8 Bil | |
ARGX
| argenx SE ADR | Jmcydgkp | Lmbc | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Xtwlzfp | Fmyx | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qzmxxkfzv | Cdxsb | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vttkhflbq | Rxgrnj | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xtvqkgdvj | Xwfkzv | $12.4 Bil | |
INCY
| Incyte Corp | Bhvkrmgd | Mmytq | $11.9 Bil |